Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 10/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978946 | 0.82 | PPARD (0.47) | — | |
| SCHEMBL978748 | 0.80 | TSHR (0.41) | LTB4R | |
| SCHEMBL977423 | 0.80 | PPARD (0.49) | LTB4R | |
| SCHEMBL12909780 | 0.74 | L3MBTL1 (0.43) | ESR1ESR2TLR8 | |
| SCHEMBL899234 | 0.72 | KCNH2 (0.55) | LTB4RTLR8 | |
| SCHEMBL20069351 | 0.71 | KCNH2 (0.42) | ESR1 | |
| SCHEMBL27977748 | 0.70 | KCNH2 (0.58) | ESR1LTB4R | |
| SCHEMBL27769288 | 0.70 | KCNH2 (0.58) | ESR1LTB4R | |
| SCHEMBL22075892 | 0.70 | ESR1 (0.49) | ARESR1ESR2 | |
| SCHEMBL22075713 | 0.70 | ESR1 (0.49) | ARESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184277-B1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2015-07-01 | — | — | EP | disclosed |
| US-8759355-B2 | Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. (CN) | 2014-06-24 | — | — | US | disclosed |
| US-20110009427-A1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INSTITUE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2011-01-13 | — | — | US | disclosed |
| EP-2184277-A1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2010-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009427-A1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | PPARD, PPARG, PPARA | AR 511/4885ESR1 2070/4885ESR2 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.